8-K: Acrivon Therapeutics Appoints Adam Levy as CFO, Rasmus Holm-Jorgensen Steps Down

Acrivon Therapeutics announces the appointment of Adam Levy as Chief Financial Officer, effective April 1, 2025, following the departure of Rasmus Holm-Jorgensen.

Summary

• Acrivon Therapeutics has appointed Adam Levy as its new Chief Financial Officer, effective April 1, 2025.
• Levy, who previously served as Senior Vice President and Head of Corporate Affairs and Investor Relations at Acrivon, will also serve as the Principal Financial Officer.
• Rasmus Holm-Jorgensen, the current CFO, is stepping down on April 1, 2025, for personal reasons to pursue an opportunity in Europe.
• Levy's compensation includes an annual salary of $490,000 and eligibility for a 40% annual performance bonus.
• He will also receive an equity grant of 35,209 stock options that vest over four years.
• Acrivon will reimburse Levy for relocation expenses up to $50,000 as he relocates to the Boston area near the company's headquarters.

Sentiment

Score: 7

Explanation: The announcement is neutral to positive. A smooth transition is expected with an internal candidate stepping into the CFO role. The departing CFO is leaving for personal reasons, indicating no underlying issues with the company.

Positives

• Adam Levy's appointment brings over 25 years of finance and investor relations experience in the biopharma industry to the CFO role.
• Levy's previous experience includes roles at Zentalis Pharmaceuticals, Turning Point Therapeutics (acquired by Bristol Myers Squibb for $4.1 billion), Gilead Sciences, Pfizer Inc., Novartis AG, and Alexion Pharmaceuticals.
• The transition appears amicable, with Holm-Jorgensen leaving for personal reasons and not due to any disagreement with the company.

Risks

• The company will need to manage the transition effectively to ensure continuity in financial leadership.
• Levy must relocate to the Boston area within nine months, and failure to do so could present challenges.

Future Outlook

The company expects a smooth transition in financial leadership with Adam Levy assuming the CFO role.

Management Comments

• Peter Blume-Jensen, President and Chief Executive Officer, expressed appreciation for Adam Levy's service and dedication to the Company.

Industry Context

Executive transitions are common in the biopharmaceutical industry, and this change at Acrivon appears to be a planned and orderly succession.

Comparison to Industry Standards

• Executive compensation packages in the biopharmaceutical industry typically include a base salary, performance-based bonus, and equity grants.
• Adam Levy's compensation appears to be in line with industry standards for a CFO role at a company of Acrivon's size and stage.
• For example, CFOs at comparable companies like Relay Therapeutics or Black Diamond Therapeutics have similar compensation structures.

Management Changes

Stakeholder Impact

• Shareholders may view the CFO transition as a neutral event, given the internal promotion and the departing CFO's stated reasons for leaving.
• Employees may experience a period of adjustment as the new CFO takes over.
• The company's financial relationships with suppliers and creditors are not expected to be significantly impacted by this change.

Key Dates